OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Triple-negative Breast Cancer (tnbc)
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Triple Negative Breast Cancer, although ER/PR 1-9% is allowed
- Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles
- An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization
You may not be eligible for this study if the following are true:
-
- Residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy
- Use of investigational anti-cancer agents
- Pregnant or nursing
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.